2 December 2021 - - US-based commercial stage, oncology-focused biopharmaceutical company Aveo Oncology (NASDAQ: AVEO) has appointed Jeb Ledell as chief operating officer, the company said.

In this role, he will be responsible for overseeing operational functions key to maximizing the company's organizational efficiency and advancing its pipeline of products.

Ledell joins Aveo from Enzyvant Therapeutics, a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases, where he served as chief operating officer and led key business operations during the recent US Food and Drug Administration approval of Rethymic.

Prior to Enzyvant, Ledell served as the chief operating officer at Compass Therapeutics and Horizon Discovery Group.

He was responsible for leading operations at both organizations through several changes in scale.

Prior to Horizon, he held multiple technology, operations and development roles at Zalicus Inc.

Ledell holds a BS degree in Chemical Engineering from Worcester Polytechnic Institute.

Aveo is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer.

Aveo currently markets Fotivda (tivozanib) in the US for the treatment of adult patients with relapsed or refractory renal cell carcinoma following two or more prior systemic therapies.

Aveo continues to develop Fotivda in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development.

Aveo is committed to creating an environment of diversity, equity and inclusion to diversify representation within the company.